With Merck veterans at the helm, Nektar launches subsidiary for pain compound

Nektar has been signaling for months that it planned to create a subsidiary to house analgesic NKTR-181, with a financial partner on board to fuel a commercial launch. Now that it has launched Inheris, the new wholly owned subsidiary,

Read the full 391 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE